Zinzino reports marginal revenue growth for October
Zinzino Group's October revenue rose by 1% to SEK 328.7 million. Despite the flat monthly performance, year-to-date revenue shows a 19% increase compared to 2025.
Zinzino AB recorded a total group revenue of SEK 328.7 million in October, marking a modest 1% increase over the same period last year. The group's primary sales operations accounted for SEK 325.1 million of this total, while subsidiary Faun Pharma contributed SEK 3.6 million, reflecting a 33% increase in external sales for the subsidiary.
The company’s regional performance varied significantly. North American operations saw a substantial 46% growth, while Asian and Pacific markets grew by 17%. Conversely, more established markets faced headwinds, with Nordic sales falling 20% and Baltic sales declining by 33% compared to October 2025.
For the first ten months of 2026, the company’s accumulated revenue reached SEK 3,128 million, representing a 19% increase over the same period in 2025. The long-term growth trajectory remains supported by expansion efforts in the Americas and Asia, offsetting the recent stagnation observed in European regions.